NCT02022787

Brief Summary

This study was designed as a pilot study to try and find a Chemokine that may be specific for renal cell carcinoma

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 30, 2013

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 30, 2013

Completed
2 days until next milestone

Study Start

First participant enrolled

January 1, 2014

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
Last Updated

March 5, 2015

Status Verified

March 1, 2015

Enrollment Period

2.8 years

First QC Date

October 30, 2013

Last Update Submit

March 4, 2015

Conditions

Clear Cell Renal Cell Carcinoma

Keywords

RCCChemokinesnephrectomypartial nephrectomy

Outcome Measures

Primary Outcomes (1)

  • Measurement of the titers of chemokines before and after tumor resection

    before nephrectomy (day of surgery)

Study Arms (1)

Renal cell carcinoma

Patients with renal cell carcinoma scheduled for partial or radical nephrectomy

Other: patients with renal cell carcinoma

Interventions

patients with renal cell carcinomaOTHER

Chemokines that may be elevated in patients with RCC

Renal cell carcinoma

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients scheduled for partial or radical nephrectomy

You may qualify if:

  • Patients with renal cell carcinoma of one or both kidneys scheduled for surgical resection

You may not qualify if:

  • Males with elevated PSA (prostatic specific antigen ) Any other untreated malignancy -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Carmel Medical Center

Haifa, 34362, Israel

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Renal tumor tissue and patients' serum

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Avi Stein, M.D.

    Carmel Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

October 30, 2013

First Posted

December 30, 2013

Study Start

January 1, 2014

Primary Completion

November 1, 2016

Study Completion

November 1, 2016

Last Updated

March 5, 2015

Record last verified: 2015-03

Locations

IL(1)